PioLigOn represents a completely new approach to the discovery of therapeutic peptides and hit molecules in general. Our VPDesigner42™ platform consists of in silico method and complementary chemistry. What sets VPDesigner42™ apart from other methods is the use of an unlimited number of different amino acids in designed peptides and unmatched speed. It can significantly boost hit and lead discovery for difficult targets and make the discovery process more environmentally friendly. We have completed multiple proof of concept studies and are looking for new customers for our technology in need of drug prototypes including targeted cargo delivery, radiotherapeutics and hit discovery for protein-protein interactions.
VPDesigner42™ is a new computational approach to drug design capable of screening trillions of unnatural peptides within days and providing first hits within hours. Our approach allows for the exploration of vast chemical space resulting in molecules containing a broader range of unnatural amino acids. This increases the chances of a good hit or lead for complicated targets. VPDesigner42™ includes complementary small-scale synthesis and verification which sets it apart from methods relying just on AI/ML.
Our platform let us to explore enormous chemical space at once (500+ unnatural amino acids rather than just 20-30). VPDesigner42™ opens new possibilities for biotech companies trying to address targets that are too complex for small molecules, yet not accessible for biologics. This has never been done in silico for peptides. At the same time, we reduce the number of experiments that need to be done in this phase to just a few, making the process of drug discovery sustainable like never before.
VPDesigner42™ is a new computational approach to drug design capable of screening trillions of unnatural peptides within days and providing first hits within hours. Our approach allows for the exploration of vast chemical space resulting in molecules containing a broader range of unnatural amino acids. This increases the chances of a good hit or lead for complicated targets. VPDesigner42™ includes complementary small-scale synthesis and verification which sets it apart from methods relying just on AI/ML.
Our platform let us to explore enormous chemical space at once (500+ unnatural amino acids rather than just 20-30). VPDesigner42™ opens new possibilities for biotech companies trying to address targets that are too complex for small molecules, yet not accessible for biologics. This has never been done in silico for peptides. At the same time, we reduce the number of experiments that need to be done in this phase to just a few, making the process of drug discovery sustainable like never before.
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
